ClinicalTrials.gg
CompletedNCT01161264Updated Mar 10, 2021

Safety and Immunogenicity of Influenza Vaccine (Surface Antigen, Inactivated) Ph.Eur, Formulation 2010/2011, When Administered to Adult and Elderly Subjects

A Phase 3 interventional study of Influenza Vaccine (Surface Antigen, Inactivated) Ph.Eur, Formulation 2010/2011 in Seasonal Influenza, sponsored by Novartis Vaccines. Completed at 1 site in Germany. Open to participants aged 18 Years and older, including healthy volunteers. Per ClinicalTrials.gov, last updated 2021-03-10.

Sponsored by Novartis Vaccines (formerly part of Novartis) · Phase 3, Interventional, and Treatment

How we know

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
126
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 101 studies in Influenza, Human by Novartis — none open to participants now, none under way, none of them phase 3. Influenza, Human · Novartis.

Enrollment
61st of 97
126 · median 270
Started
2010
with 11 others
Phase 3
39 of 101
none open now
Registered
71st of 101
by date

Among the 101 studies in Influenza, Human by Novartis, this one is the 61st largest by enrollment of the 97 interventional ones that give a count, is one of 12 that started in 2010, is one of 39 in phase 3, and was the 71st registered.

Influenza, Human

2,361 studies on the registry are indexed under Influenza, Human; 186 are open to participants now.

Browse Influenza, Human studies →

Open to participants now

None of the 101 studies in Influenza, Human by Novartis is open now. The open studies under Influenza, Human, anywhere →

Who these studies take

Of the 124 Influenza, Human studies recruiting now, 67 (54%) set no upper age limit and 47 (38%) stop at 75 or younger; 34 take children under 18; 69 take healthy volunteers.

This study: 18 Years and older · all sexes · healthy volunteers too.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Download CSVNarrow it in search →With an account: the 101 studies in Influenza, Human by Novartis as a file.
02

Study summary

Influenza poses a significant threat to individual and public health, and influenza vaccination with a trivalent inactivated influenza vaccine is widely recommended to children, adults at risks and elderly. Due to antigenic changes of influenza viruses, the virus strains used in interpandemic influenza vaccines are adjusted every year according to WHO (World Health Organization) and CHMP (Committee for Medicinal Products for Human Use) recommendations. Following a change in the vaccine antigen composition recommendation from the previous season, immunogenicity and tolerability of the newly composed vaccines are subject of evaluation in an annual clinical trial in non-elderly adult and elderly subjects according to the guidelines set by EMEA (CPMP/BWP/214/96).

03

Conditions studied

  • Seasonal Influenza

Browse trials for

Keywords

  • Elderly
  • Influenza
  • Immunogenicity
  • Safety
  • Influenza vaccine
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
Yes

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Male and female volunteers of 18 years of age and older, mentally competent, willing and able to give written prior to study entry;
  2. Individuals able to comply with all the study requirements;
  3. Individuals in good health as determined by medical history, physical examination and clinical judgment of the investigator.

Exclusion criteria

Exclusion Criteria:

  1. Individuals with behavioral or cognitive impairment or psychiatric disease that, in the opinion of the investigator, may interfere with the subject's ability to participate in the study;
  2. Individuals with any serious chronic or acute disease (in the judgment of the investigator), including but not limited to:

    1. Cancer, except for localized skin cancer;
    2. Advanced congestive heart failure;
    3. (COPD);
    4. disease (including rheumatoid arthritis);
    5. Acute or progressive hepatic disease;
    6. Acute or progressive renal disease;
    7. Severe neurological or psychiatric disorder;
    8. Severe asthma;
  3. Individuals with history of any anaphylactic reaction and/or serious allergic reaction following a vaccination, a proven to any component of the study vaccine (e.g. to ovalbumin, chicken protein, chicken feathers, influenza viral protein, polymyxin, neomycin);
  4. Individuals with known or suspected (or have a high risk of developing) impairment/alteration of immune function (excluding that normally associated with advanced age) resulting, for example, from:

    1. receipt of therapy (any parenteral or oral or cancer chemotherapy/radiotherapy) within the past 60 days and for the full length of the study;
    2. receipt of immunostimulants;
    3. receipt of parenteral immunoglobulin preparation, blood products and/or plasma derivates within the past 3 months and for the full length of the study;
    4. suspected or known infection or HIV-related disease;
  5. Individuals with known or suspected history of drug or alcohol abuse;
  6. Individuals with a bleeding diathesis or conditions associated with prolonged bleeding time that in the investigator's opinion would interfere with the safety of the subject;
  7. Female who are pregnant or nursing (breastfeeding) mothers or females of childbearing age do not plan to use acceptable measures, for the duration of the study. Adequate contraception is defined as hormonal (e.g., oral, injection, transdermal patch, implant, cervical ring), barrier (e.g., condom with spermicide or diaphragm with spermicide), intrauterine device (IUD), or monogamous relationship with vasectomized partner who has been vasectomized for 6 months or more prior to the subject's study entry;
  8. Individuals who are not able to comprehend and to follow all required study procedures for the whole period of the study;
  9. Individuals that within the past 12 months have received more than one injection of influenza vaccine;
  10. Individuals that within the past 6 months have:

    1. had laboratory confirmed seasonal or pandemic influenza disease;
    2. received seasonal or pandemic influenza vaccine;
  11. Individuals with any acute or chronic infections requiring systemic antibiotic treatment or antiviral therapy within the last 7 days;
  12. Individuals that have experienced fever (i.e., axillary temperature ≥38°C) within the last 3 days of intended study vaccination;
  13. Individuals participating in any clinical trial with another product 4 weeks prior to first study visit or intent to participate in another clinical study at any time during the conduct of this study;
  14. Individuals who received any other vaccines within 4 weeks prior to enrollment in this study or who are planning to receive any vaccine within 4 weeks from the study vaccines;
  15. Individuals who have received blood, blood products and/or plasma derivatives or any parenteral immunoglobulin preparation in the past 12 weeks and for the full length of the study;
  16. Individuals who are part of study personnel or close family members conducting this study;
  17. Individuals with history or any illness that, in the opinion of the investigator, might interfere with the results of the study or pose additional risk to the subjects due to participation in the study;
  18. > 35 kg/m2.
Terms in these criteria, in plain language(10)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

COPD

Chronic obstructive pulmonary disease: long-term lung disease that makes it hard to breathe out, including emphysema and chronic bronchitis.

Autoimmune disease

A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.

Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

Immunosuppression

A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.

Read whether the line is about a condition or about medicines, and which medicines and doses it means.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Single group
Masking
None (open label)
Enrollment
126 participants (actual)

Study arms

  • Experimental
    18-60 YOA

    Biological: Influenza Vaccine (Surface Antigen, Inactivated) Ph.Eur, Formulation 2010/2011

  • Experimental
    ≥ 60 YOA

    Biological: Influenza Vaccine (Surface Antigen, Inactivated) Ph.Eur, Formulation 2010/2011

Interventions

  • BiologicalInfluenza Vaccine (Surface Antigen, Inactivated) Ph.Eur, Formulation 2010/2011

    Single 0.5 mL dose administered into the deltoid muscle of (preferably) the non-dominant arm on Day 1.

06

What researchers measure

Primary outcomes

  1. Antibody response to each influenza vaccine antigen as measured by hemagglutination inhibition at 21 days post immunization

    Time frame: 22 days

07

Study locations

1 site
  • Novartis Investigational Site
    Germany, Germany
08

References and documents

09

Timeline

Tracking since Sep 25, 2026
Not marked actual or estimatedDates not marked actual or estimated

The record gives a start of Jul 2010, a primary completion of Jul 2010 and a completion of Jul 2010. It does not say whether these dates are actual or estimated.

How these figures are worked out, and which studies are left out of them.

Registered
Jul 12, 2010
First posted
Jul 13, 2010
Start
Jul 2010
Primary completionActual
Jul 2010
CompletionActual
Jul 2010
Last update
Mar 10, 2021
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Mar 10, 2021, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT01161264
Lead sponsor
Novartis Vaccines
Responsible party
Sponsor
First posted
Jul 13, 2010
Start date
Jul 2010
Primary completion
Jul 2010
Completion
Jul 2010
Last update
Mar 10, 2021

Oversight

FDA-regulated drug
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Sep 2011. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion